Library

Your search history is empty.
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 58 (1980), S. 551-556 
    ISSN: 1432-1440
    Keywords: Plasmapheresis ; Plasma separation ; Membranes for filtration ; Goodpasture's syndrome ; Hyperproteinemia ; Plasmapherese ; Plasmaseparation ; Proteinfiltration durch Membranen ; Goodpasture Syndrom ; Hyperproteinämie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Plasmaseparation wurde mit Hilfe von Zellulose-Diacetat-Hohlfasermodulen durchgeführt. Die Porengröße der Membranen betrug 0.2 µm und hatte eine obere Ausschlußgrenze von ungefähr 3 Millionen Dalton. Fünf Liter Filtrat konnten durchschnittlich in 80 min separiert werden. Der Proteingehalt des Filtrates lag bei etwa 60% des Proteingehaltes im Blut. Die Realtionen der Immunglobuline unterschieden sich im Plasma und im Filtrat nur gering. Durch eine Plasmaseparation gelang es, die Konzentration an Immunglobulinen auf etwa 40% der initialen Konzentration zu senken.
    Notes: Summary Plasma separation was carried out using a new cellulose diacetate hollow-fibre module. The pore size of the membranes used was 0.2 µm and the cut-off at approximately 3 million dalton. Five litres of filtrate was separated in 80 min. The protein content of the filtrate was 60% of that in the blood plasma. When plasma and filtrate were compared, there was little difference in the proportions of the immunoglobulins. At the end of treatment, the immunoglobulin content of the plasma had been reduced to 40% of its initial concentration.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 61 (1983), S. 1001-1010 
    ISSN: 1432-1440
    Keywords: Rapidly progressive glomerulonephritis (RPGN) ; Goodpasture's syndrome ; Immunosuppression ; Anticoagulant therapy ; Pulse therapy ; Plasmapheresis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Of 30 therapy studies which distinguish between improved and non-improved renal function, 350 patients with rapidly progressive glomerulonephritis (RPGN) were evaluated. Pure descriptions of cases were not included. The cases of RPGN were divided into autoantibody-induced and non-autoantibody-induced groups. This latter group was subdivided into idiopathic and symptomatic RPGN. A further distinction was drawn between the different forms of symptomatic RPGN, but no separate evaluations were made, on account of the small numbers of cases. Therapies were divided into immunosuppression, anticoagulant therapy, pulse therapy, and therapeutic plasmapheresis. In autoantibody-induced RPGN, improved renal function was evidenced in only five cases out of 27. In contrast to this, 66% of the non-oliguric patients with creatinine levels 〉6 mg/dl showed improved renal function after plasma separation. In non-autoantibody-induced RPGN, the least favourable results were shown by anticoagulant treatment, where improvement in renal function was produced in only 34% of the cases treated, and haemorrhagic complications occurred in 25%, about half of which had a fatal outcome. Under pulse therapy, 27 out of 38 patients (71%) showed improvement, as against 59 out of 93 (63%) under plasmapheresis. In contrast to the situation in autoantibody-induced RPGN, it is possible in non-autoantibody-induced RPGN to achieve therapy-induced improvement also in a high percentage of cases where terminal renal insufficiency is present, and even when dialysis treatment has just been commenced. The collected statistics for therapeutic results achieved in RPGN are compared and contrasted with two controlled studies which showed diverging findings.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-1440
    Keywords: Calcium carbonate ; Phosphate ; Chronic renal failure ; Aluminium ; Hyperparathyroidism
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Calcium carbonate has been successfully used as a phosphate binder in patients with chronic renal failure; however, a high frequency of hypercalcaemia has been reported. To study the effects of calcium carbonate preparations with different dissolution characteristics on the incidence of this side effect, we conducted a double-blind, crossover trial in 21 patients undergoing chronic haemodialysis. Aluminium hydroxide therapy was replaced with calcium carbonate. The subjects then randomly received either an enteric-coated or a gastric-coated preparation. Calcium carbonate (3.1–3.6 g/d) controlled serum phosphate concentrations as effectively as aluminium hydroxide (2.9 g/d). Concurrently, there was a significant rise in mean serum calcium and a fall in serum concentrations of both parathyroid hormone and osteocalcin, the latter suggesting a decrease in bone turnover. Overall, hypercalcaemic episodes developed in 9 patients (43%) and occurred at a considerable frequency (33 episodes per 100 patient-months) during treatment with the gastric-coated formulation. Following conversion to enteric-coated calcium carbonate (3.6 g/d) patients had fewer occurrences of hypercalcaemia (12 episodes per 100 patient-months,P〈0.05) and, as compared to the gastric-coated preparation, increases in serum calcium 〉3.00 mmol/l were not observed at all. Hyperaluminaemia was regressive during therapy with calcium carbonate, but addition of small doses of aluminium hydroxide caused a large rise in serum aluminium concentrations after infusion of desferrioxamine, indicating an enhanced rate of absorption or aberrant compartmentalization of aluminium. We conclude that calcium carbonate can control hyperphosphataemia in dialysis patients. However, undesirable hypercalcaemic episodes may occur, the frequency and severity of which can be lowered by the use of an enteric-coated preparation. Concomitant use of aluminium hydroxide and calcium carbonate should be restricted to patients in whom the degree of aluminium accumulation is monitored by serial desferrioxamine tests.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...